Table 5 Comparison of demographic and clinical characteristics of participants recruited pre-legalization with and without cannabis urine screen data
| Characteristic |
Total pre-legalization sample (n = 602) |
Pre-legalization sample with cannabis urine drug screens followed through post-legalization period (n = 199) |
|---|---|---|
| Age in years; mean (SD) | 38.9 (10.4) | 40.6 (11.1) |
| Male sex; n (%) | 343 (57) | 97 (48.7) |
| Type of MAT; n (%) | ||
| → Methadone | 498 (82.9) | 171 (85.9) |
| → Buprenorphine | 103 (17.1) | 28 (14.1) |
| Dose (mg/day); median (IQR) | ||
| → Methadone | 65 (61) | 75 (63) |
| → Buprenorphine | 12 (8) | 12 (7) |
| Length of time in treatment (years); median (IQR) | 2 (4.9) | 3 (5) |
| Opioid abstinencea; n (%) | 176 (29.2) | 66 (33.2) |
| Percentage of opioid-positive urine drug screens amongst non-abstainersa; mean (SD) | 21.1 (23.3) | 16.5 (18.7) |
| Self-reported cannabis use; n (%) | 330 (54.8%) | 111 (55.8) |
| Days of use in the last 30 days amongst users; median (IQR) | 30 (16) | 30 (15) |